UCB Gets US FDA Approval for Psoriasis Drug
By Helena Smolak
UCB received approval from the U.S. Food and Drug Administration for a drug to treat severe plaque psoriasis for which the company expects global peak annual sales of at least 4 billion euros ($4.23 billion).
The Belgian biopharmaceutical firm said Wednesday that its bimekizumab drug, which will be commercialized as Bimzelx, was approved by the FDA as a treatment for the skin disease psoriasis in adults.
"With bimekizumab now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S.", it said.
The FDA approval was backed by data from three Phase 3 studies, the company said.
UCB on Tuesday said the FDA approved its Zilbrysq for the treatment of adults with myasthenia, an autoimmune disorder.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
October 18, 2023 11:21 ET (15:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now